Modality
Multispecific
MOA
FXIai
Target
C5
Pathway
Wnt
RAPsALN
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
~Jul 2017
→ ~Oct 2018
NDA/BLA
~Jan 2019
→ ~Apr 2020
Approved
Jul 2020
→ Jul 2025
ApprovedCurrent
NCT08967560
1,347 pts·RA
2022-07→2025-07·Recruiting
NCT07470754
2,215 pts·RA
2020-07→2025-06·Not yet recruiting
3,562 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2025-06-189mo agoPh3 Readout· RA
2025-07-238mo agoPh3 Readout· RA
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Approved
Not yet…
Approved
Recruit…
Catalysts
Ph3 Readout
2025-06-18 · 9mo ago
RA
Ph3 Readout
2025-07-23 · 8mo ago
RA
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08967560 | Approved | RA | Recruiting | 1347 | ACR20 |
| NCT07470754 | Approved | RA | Not yet recr... | 2215 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-6035 | Bayer | Phase 1 | C5 |